Suwitchaya Sirimanakul

Ms. Suwitchaya Sirimanakul

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
KIKwanpet Intasurat
Kwanpet Intasurat
NSNonth Submunkongtawee
Nonth Submunkongtawee
PLPhoomintara Longsompurana
Phoomintara Longsompurana
ATApisitt Thaiprayoon
Apisitt Thaiprayoon
WKWarisara Kasemsukwimol
Warisara Kasemsukwimol
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
The urgent need for an effective COVID-19 therapy has propelled the exploration of innovative strategies to combat the fast-mutating SARS-CoV-2 virus. This study attempted to develop nanobodies (Nbs) against the SARS-CoV-2 Omicron variants by redirecting the 1.29 neutralizing Nb, a receptor-binding domain (RBD)-specific Nb that can protect against various SARS-CoV-2 variants other than Omicron, to target SARS-CoV-2 Omicron subvariant BA.5, the variant used for the development of the bivalent vaccine. Error-prone libraries of the 1.29 Nb were constructed. Following two rounds of selection using the functional ligand-binding identification by Tat-based recognition of associating proteins (FLI-TRAP) technique, we rapidly identified two Nbs, namely, C11 and K9, that could target the RBD of the Omicron subvariant BA.5, XBB.1.5, and XBB.1.16 subvariants. Molecular docking provided insights into how these Nbs interact with the RBD of the BA.5 and JN.1 variants. The application of directed evolution via utilization of error-prone PCR and the synthetic E. coli applied in the FLI-TRAP selection method may be a powerful tool for facilitating simple, fast and economical selection to redirect existing antibodies and to generate antibody fragments to target proteins susceptible to autonomous mutation, not only for viral infection but also other diseases, such as cancer.


5 June 2026 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
SSSuwitchaya Sirimanakul
Suwitchaya Sirimanakul
JHJoseph D. Hurley
Joseph D. Hurley
NVNakarin Vutipow
Nakarin Vutipow
FLFabien Loison
Fabien Loison
AKAnongnard Kasorn
Anongnard Kasorn
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
Heart failure (HF) is a major global health concern, particularly in low- and middle-income countries where it is often underdiagnosed. Prognostic testing plays a crucial role in guiding treatment and monitoring disease progression. In this study, we developed an electrochemical assay-based prognostic kit for HF detection targeting soluble suppression of tumorigenicity 2 (sST2). This biomarker offers superior prognostic value compared to traditional methods as it remains stable regardless of patient demographics, including age, sex, obesity, and renal status. To reduce production costs and complexity of the test kit, single-domain antibody fragments (nanobodies) were used in place of conventional antibodies, and an electrochemical platform was used instead of ELISA. We obtained 19 candidate nanobodies from screening a naïve, fully synthetic yeast-display nanobody (Nb) library, and four of these (Nb1, Nb2, Nb5, and Nb13) were prioritized for further study on the basis of high affinity and low polyreactivity. Of these, Nb2 and Nb5 enabled sensitive electrochemical detection of sST2 with limits of detection of 3.37 and 3.00 ng/mL, respectively, in PBS buffer. Further validation using patient serum samples with the Nb5-based platform achieved quantitative detection of sST2 across a predilution concentration range from 0.75 to 93.09 ng/mL, facilitated by sample dilution to mitigate matrix effects and surface saturation. Both nanobodies exhibited high target specificity, with no observed cross-reactivity to other HF biomarkers or serum components. This novel prognostic tool can be produced and performed at low cost, providing a new option for heart failure diagnosis and treatment planning, particularly in low- and middle-income countries, where cost is a major cause of underdiagnosis.

27 November 2025
Verified
Conference Paper
Open access
SSSuwitchaya Sirimanakul
Suwitchaya Sirimanakul
NSNonth Submunkongtawee
Nonth Submunkongtawee
PKPirada Kanchanapun
Pirada Kanchanapun
NSNitichort Supadirek
Nitichort Supadirek
SOSirapat Oyadomari
Sirapat Oyadomari
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev